Skip to main content
. 2018 Apr 16;11:55. doi: 10.1186/s13045-018-0598-0

Table 3.

Multivariate analysis

HR CI p
LFS
 MUD vs Haplo 0.94 0.76–1.17 0.630
 Year of Tx 1.01 0.98–1.03 0.445
 Age (per 10 years) 1.10 0.95–1.27 0.173
 Status at Tx
  CR ≥ 2 vs CR1 1.22 1.05–1.42 0.009
  Advanced vs CR1 1.67 1.48–1.89 < 10− 4
 Cytogenetics
  Intermediate vs good 1.10 0.76–1.60 0.590
  Poor vs good 1.79 1.25–2.56 0.001
  Secondary vs good 1.49 1.06–2.08 0.019
  Missing vs good 1.40 1.01–1.95 0.043
 Female D/male R 1.09 0.93–1.27 0.247
 KPS ≥ 90% 0.85 0.76–0.96 0.009
 PBSC vs BM 1.04 0.86–1.25 0.670
 In vivo TCD 0.93 0.82–1.05 0.288
 Previous autograft 1.36 1.00–1.86 0.045
 RIC vs MAC 1.04 0.92–1.18 0.468
 Center (frailty) 0.292
OS
 MUD vs Haplo 0.87 0.68–1.10 0.244
 Year of Tx 1.01 0.98–1.04 0.392
 Age (per 10 years) 1.16 1.00–1.34 0.046
 Status at Tx
  CR ≥ 2 vs CR1 1.16 0.99–1.37 0.059
  Advanced vs CR1 1.62 1.42–1.85 < 10−4
 Cytogenetics
  Intermediate vs good 1.05 0.71–1.54 0.792
  Poor vs good 1.66 1.14–2.40 0.007
  Secondary vs good 1.40 0.99–1.98 0.057
  Missing vs good 1.32 0.94–1.87 0.105
 Female D/male R 1.14 0.97–1.34 0.093
 KPS ≥ 90% 0.83 0.74–0.94 0.003
 PBSC vs BM 1.01 0.83–1.24 0.893
 in vivo TCD 0.93 0.81–1.08 0.372
 Previous autograft 1.39 1.00–1.93 0.043
 RIC vs MAC 1.12 0.97–1.28 0.096
 Center (frailty) 0.062
RI
 MUD vs Haplo 1.06 0.76–1.47 0.699
 Year of Tx 0.99 0.96–1.03 0.790
 Age (per 10 years) 0.87 0.71–1.08 0.230
 Status at Tx
  CR ≥ 2 vs CR1 1.26 1.01–1.57 0.033
  Advanced vs CR1 1.96 1.65–2.34 < 10−4
 Cytogenetics
  Intermediate vs good 0.95 0.57–1.60 0.869
  Poor vs good 2.11 1.29–3.43 0.002
  Secondary vs good 1.35 0.85–2.14 0.202
  Missing vs good 1.31 0.83–2.06 0.241
 Female D/male R 0.88 0.69–1.11 0.285
 KPS ≥ 90% 0.96 0.82–1.14 0.711
 PBSC vs BM 1.02 0.77–1.34 0.865
 in vivo TCD 1.04 0.86–1.25 0.662
 Previous autograft 1.16 0.71–1.88 0.546
 RIC vs MAC 0.91 0.76–1.10 0.374
 Center (frailty) 0.135
NRM
 MUD vs Haplo 0.75 0.54–1.05 0.095
 Year of Tx 1.02 0.98–1.06 0.243
 Age (per 10 years) 1.34 1.10–1.63 0.003
 Status at Tx
  CR ≥ 2 vs CR1 1.18 0.94–1.47 0.135
  Advanced vs CR1 1.45 1.21–1.74 < 10−4
 Cytogenetics
  Intermediate vs good 1.29 0.75–2.22 0.353
  Poor vs good 1.46 0.84–2.51 0.172
  Secondary vs good 1.63 0.99–2.68 0.051
  Missing vs good 1.49 0.91–2.43 0.111
 Female D/male R 1.34 1.08–1.65 0.005
 KPS ≥ 90% 0.75 0.63–0.89 0.001
 PBSC vs BM 1.08 0.82–1.43 0.564
 In vivo TCD 0.85 0.70–1.04 0.122
 Previous autograft 1.62 1.07–2.46 0.022
 RIC vs MAC 1.19 0.98–1.43 0.066
 Center (frailty) 0.015
GRFS
 MUD vs Haplo 1.18 0.95–1.47 0.125
 Year of Tx 0.99 0.97–1.02 0.792
 Age (per 10 years) 1.03 0.90–1.18 0.606
 Status at Tx
  CR ≥ 2 vs CR1 1.16 1.00–1.34 0.038
  Advanced vs CR1 1.64 1.45–1.84 < 10−4
 Cytogenetics
  Intermediate vs good 1.24 0.87–1.75 0.223
  Poor vs good 1.69 1.20–2.38 0.002
  Secondary vs good 1.52 1.11–2.09 0.008
  Missing vs good 1.45 1.06–1.98 0.019
 Female D/male R 1.05 0.90–1.21 0.516
 KPS ≥ 90% 0.85 0.76–0.94 0.003
 PBSC vs BM 1.09 0.91–1.32 0.313
 In vivo TCD 0.75 0.66–0.85 < 10−4
 Previous autograft 1.32 0.97–1.80 0.072
 RIC vs MAC 1.00 0.88–1.13 0.933
 Center (frailty) 0.093
aGVHD II–IV
 MUD vs Haplo 1.17 0.82–1.65 0.374
 Year of Tx 1.00 0.96–1.04 0.845
 Age (per 10 years) 0.89 0.71–1.11 0.326
 Status at Tx
  CR ≥ 2 vs CR1 1.00 0.79–1.27 0.942
  advanced vs CR1 1.15 0.95–1.40 0.135
 Cytogenetics
  Intermediate vs good 1.34 0.77–2.34 0.296
  Poor vs good 1.45 0.83–2.53 0.180
  Secondary vs good 1.40 0.84–2.34 0.192
  Missing vs good 1.30 0.78–2.16 0.303
 Female D/male R 1.10 0.88–1.39 0.378
 KPS ≥ 90% 0.87 0.73–1.05 0.152
 PBSC vs BM 1.01 0.75–1.35 0.954
 In vivo TCD 0.70 0.57–0.85 0.001
 Previous autograft 2.18 1.42–3.36 < 10−4
 RIC vs MAC 1.02 0.82–1.25 0.853
 Center (frailty) 0.011
aGVHD III–IV
 MUD vs Haplo 1.52 0.85–2.71 0.154
 Year of Tx 0.97 0.91–1.03 0.369
 Age (per 10 years) 0.98 0.68–1.41 0.935
 Status at Tx
  CR ≥ 2 vs CR1 1.23 0.83–1.84 0.290
  Advanced vs CR1 1.78 1.31–2.43 < 10−4
 Cytogenetics
  Intermediate vs good 2.27 0.77–6.68 0.133
  Poor vs good 1.67 0.55–5.04 0.361
  Secondary vs good 2.03 0.73–5.67 0.173
  Missing vs good 1.69 0.61–4.70 0.311
 Female D/male R 1.02 0.69–1.51 0.895
 KPS ≥ 90% 0.68 0.52–0.91 0.009
 PBSC vs BM 1.20 0.71–2.02 0.478
 In vivo TCD 0.63 0.46–0.86 0.004
 Previous autograft 2.07 1.03–4.15 0.039
 RIC vs MAC 0.76 0.53–1.09 0.147
 Center (frailty) 0.054
cGVHD
 MUD vs Haplo 1.22 0.84–1.75 0.281
 Year of Tx 0.97 0.94–1.01 0.228
 Age (per 10 years) 0.99 0.80–1.23 0.964
 Status at Tx
  CR ≥ 2 vs CR1 1.05 0.84–1.30 0.669
  Advanced vs CR1 1.12 0.92–1.37 0.251
 Cytogenetics
  Intermediate vs good 1.72 1.01–2.91 0.042
  Poor vs good 1.74 1.01–2.99 0.045
  Secondary vs good 1.88 1.14–3.10 0.013
  Missing vs good 1.66 1.01–2.72 0.043
 Female D/male R 1.02 0.81–1.28 0.860
 KPS ≥ 90% 1.09 0.91–1.31 0.310
 PBSC vs BM 1.48 1.08–2.03 0.013
 In vivo TCD 0.57 0.47–0.70 < 10−4
 Previous autograft 1.64 0.99–2.70 0.050
 RIC vs MAC 0.82 0.67–1.02 0.077
 Center (frailty) 0.001
Extensive cGVHD
 MUD vs Haplo 2.02 1.17–3.47 0.011
 Year of Tx 0.97 0.92–1.02 0.298
 Age (per 10 years) 1.05 0.77–1.42 0.740
 Status at Tx
  CR ≥ 2 vs CR1 0.92 0.67–1.26 0.618
  Advanced vs CR1 0.97 0.73–1.30 0.874
 Cytogenetics
  Intermediate vs good 1.15 0.56–2.37 0.693
  Poor vs good 1.39 0.67–2.90 0.371
  Secondary vs good 1.27 0.64–2.49 0.481
  Missing vs good 1.11 0.57–2.16 0.751
 Female D/male R 0.94 0.66–1.34 0.751
 KPS ≥ 90% 1.00 0.77–1.29 0.997
 PBSC vs BM 1.30 0.83–2.05 0.245
 In vivo TCD 0.35 0.27–0.46 < 10−4
 Previous autograft 1.19 0.54–2.60 0.658
 RIC vs MAC 0.74 0.54–1.01 0.060
 Center(frailty) 0.022

Abbreviations: LFS, leukemia-free survival; OS, overall survival; RI, relapse incidence; NRM, non-relapse mortality; GRFS, graft-versus-host-free-relapse free survival; a, acute; c, chronic; GVHD, graft versus host disease; MUD, matched unrelated donor; Haplo, haploidentical; Tx, transplant; CR, complete remission; KPS, Karnofsky performance status; PBSC, peripheral blood; BM, bone marrow; D, donor; R, recipient; TCD, T cell depletion; RIC, reduced intensity conditioning; MAC, myeloablative conditioning